PBYI - Puma Bio: A Contrarian Investment That Requires Patience
Puma Biotechnology (PBYI) has been one of my more frustrating investments over the past year. I decided to take a stab at PBYI in Q4 of 2019 in anticipation the company was going to address NERLYNX’s tolerability and discontinuation rate. Well, the company has started to address these concerns and the commercial numbers show their approach is being adopted by physicians. Admittedly, I was expecting the Street and the market to praise Puma’s efforts but the share price has yet to recover. Despite my frustration, I still believe PBYI is worthy of a